AIP
AARD icon

Ameritas Investment Partners’s Aardvark Therapeutics AARD Stock Holding History

Ameritas Investment Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-578
Closed -$2.18K – 3361
2026
Q1 		$2.18K Hold
578
– – ﹤0.01% 3065
2025
Q4 		$7.59K Hold
578
– – ﹤0.01% 2965
2025
Q3 		$7.68K Hold
578
– – ﹤0.01% 2996
2025
Q2 		$7.82K Buy
+578
New +$5.96K ﹤0.01% 3040

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Ameritas Investment Partners's AARD Position: Q2 2026 in Review

Ameritas Investment Partners sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 578 shares — an estimated $2.18K sold.

Ameritas Investment Partners first reported a position in AARD in Q2 2025 and held it in 4 quarters. The position peaked at $7.82K in Q2 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Ameritas Investment Partners reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ameritas Investment Partners sold 578 Aardvark Therapeutics shares in Q2 2026, an estimated $2.18K.
  • Ameritas Investment Partners first reported a position in Aardvark Therapeutics in Q2 2025 and held it in 4 quarters.
  • Ameritas Investment Partners's Aardvark Therapeutics position peaked at $7.82K in Q2 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.